Nuvation Bio Inc.

Quick facts

Phase 2 pipeline

• AB-106 · Oncology
  AB-106 is a TGF-β receptor inhibitor that blocks transforming growth factor-beta signaling to modulate immune responses and reduce fibrosis.

Phase 1 pipeline

• AB-106, digoxin · Cardiovascular
  Digoxin inhibits the sodium-potassium ATPase pump.
• AB-106, Itraconazole · Infectious Disease
  Inhibits fungal cytochrome P450 14α-demethylase
• AB-106, Rifampicin · Infectious Disease
  Inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase
• DS6051b
• NUV-1511

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Nuvation Bio Inc. portfolio CI brief
• Nuvation Bio Inc. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies